Stay updated on PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial
Sign up to get notified when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.

Latest updates to the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page
- CheckyesterdayChange DetectedThe page has removed a citation regarding improved survival with ipilimumab in patients with metastatic melanoma, which is a significant change in core content.SummaryDifference0.1%
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe webpage has undergone significant content changes, including the removal of detailed descriptions of a clinical trial for Pembrolizumab in NSCLC and the addition of a new revision number. The principal investigator's name has also been retained, but the overall trial details have been significantly reduced.SummaryDifference15%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
Stay in the know with updates to PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PEOPLE: Pembrolizumab in Low PD-L1 NSCLC Clinical Trial page.